Radioactive drug RYZ401 takes aim at neuroendocrine tumors in first human trial
NCT ID NCT07165132
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers radiation directly to cancer cells. The study will enroll about 104 adults to find the safest dose and see if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Facility
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Facility
RECRUITINGLexington, Kentucky, 40536, United States
-
Research Facility
RECRUITINGSt Louis, Missouri, 63104, United States
-
Research Facility
RECRUITINGSt Louis, Missouri, 63110, United States
-
Research Facility
RECRUITINGColumbus, Ohio, 43210, United States
-
Research Facility
RECRUITINGNashville, Tennessee, 37232, United States
-
Research Facility
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Research Facility
RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
Research Facility
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RYZ401 (a radioactive drug containing Actinium-225)
What this could lead to
If successful, this could lead to a new treatment option for people with neuroendocrine tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 104 participants, so the drug may not work or could have serious side effects. The radioactive nature of the drug also carries risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.